J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says
Source:
bloombergMarkets
June 17, 2026 · 12:37
Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk. (Source: Bloomberg)
The original article opens on the publisher's website.
More from Economy
View topic →China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says
cnbc
Sep 1, 2026 · 16:52
US diesel prices soar as Trump hauls in refiners
financialTimes
Sep 1, 2026 · 14:18
Anthropic's Claude Fable 5.1 and Mythos 5.1 arrive with a 75% cost reduction for Fable cache reads
ventureBeat
Sep 1, 2026 · 11:41
Prediction market traders think job creation rebounded in August
cnbc
Sep 1, 2026 · 11:16
Your files stay put: Perplexity’s hybrid AI keeps confidential data off the cloud
ventureBeat
Sep 1, 2026 · 08:00